Trexquant Investment LP decreased its position in shares of Merus (NASDAQ:MRUS - Free Report) by 8.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,733 shares of the biotechnology company's stock after selling 9,711 shares during the period. Trexquant Investment LP owned 0.15% of Merus worth $4,236,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the business. Avior Wealth Management LLC acquired a new position in Merus in the 4th quarter worth approximately $76,000. MML Investors Services LLC acquired a new position in shares of Merus during the 3rd quarter worth about $206,000. Gordian Capital Singapore Pte Ltd lifted its stake in Merus by 10.4% in the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company's stock valued at $250,000 after buying an additional 470 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Merus by 10.9% in the 4th quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock worth $337,000 after buying an additional 789 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Merus during the 4th quarter worth approximately $347,000. Institutional investors and hedge funds own 96.14% of the company's stock.
Merus Trading Down 4.5 %
Shares of MRUS traded down $1.78 during midday trading on Thursday, reaching $37.78. 212,713 shares of the company were exchanged, compared to its average volume of 707,755. The company has a market cap of $2.61 billion, a price-to-earnings ratio of -9.51 and a beta of 1.02. Merus has a 1-year low of $33.19 and a 1-year high of $61.61. The stock has a 50-day moving average price of $43.64 and a 200-day moving average price of $45.35.
Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. Equities research analysts anticipate that Merus will post -3.85 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on MRUS shares. HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price target on shares of Merus in a research note on Monday, March 3rd. Piper Sandler began coverage on shares of Merus in a research report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price for the company. Wells Fargo & Company began coverage on shares of Merus in a research report on Friday, February 7th. They set an "overweight" rating and a $91.00 price target on the stock. Guggenheim reiterated a "buy" rating and issued a $109.00 price objective on shares of Merus in a report on Friday, March 28th. Finally, Bank of America lowered their target price on Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $85.31.
Get Our Latest Research Report on MRUS
Merus Profile
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
